Journals / Retina-Vitreus / 2009 / Cilt: 17 - Sayı: 2

Two cases of anterior ischaemic optic neuropathy associated with interferon-alpha treatment

İnterferon-alfa ile ilişkili anterior iskemik optik nöropati

Pages
149–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After stoping of interferon alpha treatment, clinical symptomps regressed but optic atrophy developed in both cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Interferons are natural glicoprotein structured citokins used in mainly chronic viral hepatitis, solid tumors and hematological malignancies, they are used in wide range of other indications.
📊
Key Findings & Data:In this paper, we introduce two cases who are on interferon  and ribavirin treatment with choronic hepatitis-c indication, but those who have developed single sided blindness during this treatment and resulted in optic neuropathy at follow up examinations.
💡
Conclusion & Impact:After stoping of interferon alpha treatment, clinical symptomps regressed but optic atrophy developed in both cases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kadın · Optik nöropati · iskemik

Abstract

Interferons are natural glicoprotein structured citokins used in mainly chronic viral hepatitis, solid tumors and hematological malignancies, they are used in wide range of other indications. Various sistemic and ocular adverse effects occus during interferon treatment. However, adverse effetcs are mild but sometimes serious even fatal. In this paper, we introduce two cases who are on interferon  and ribavirin treatment with choronic hepatitis-c indication, but those who have developed single sided blindness during this treatment and resulted in optic neuropathy at follow up examinations. After stoping of interferon alpha treatment, clinical symptomps regressed but optic atrophy developed in both cases.

Özet

İnterferonlar, doğal glikoprotein yapılı sitokinler olup başta kronik viral hepatitler, solid tümörler ve hematolojik malignensiler olmak üzere geniş kullanım alanları vardır. Ancak interferon tedavisi sırasında değişik sistemik ve oküler yan etkiler ortaya çıkabilmektedir. Yan etkiler genellikle geri dönüşümlü ve hafif olmakla birlikte ciddi hatta ölümcül olabilmektedir. Bu yazıda kronik hepatit C enfeksiyonu tanısıyla interferon  ve ribavirin tedavisi alan ancak tedavi sırasında tek taraflı görme kaybı ortaya çıkan ve yapılan muayene-tetkikler sonucunda anterior iskemik optik nöropati teşhisi konulan iki olgu sunulmuştur. Her iki olguda da interferon  tedavisinin kesilmesiyle klinik bulguların gerilediği ve takiplerde optik atrofi geliştiği izlendi.

🔖

Cite This Article

ARGIN, M. A., DİNÇ, E., YILMAZ, A., ALTINTAŞ, E., PATA, C., ÖZGE, A. (2009). Two cases of anterior ischaemic optic neuropathy associated with interferon-alpha treatment. Retina-Vitreus, Cilt: 17 - Sayı: 2, 149–152. https://ajindex.com/articles/305207

References (18)

  1. Balkwill FR.: Interferons. Lancet. 1989;1:1060-1063
  2. Streuli M, Nagata S, Weisssman C.: At least three human type interferons: structure two. Science. 1980;209:1343-1346
  3. Yoav V, Yifat L, Anat L, et al.: Interferon- associated bilateral simultaneous ischemic optic neuropathy J Neuro-Ophthalmol, 2003;23:4
  4. Manesis EK, Petrou C, Brouzas D, et al.: Optic tract neuropathy complicating low-dose interferon treatment. Journal of Hepatology. 1994;21:474-477
  5. Fontaine H, Pol S.: Side effects of interferon- in treating hepatitis C virus infection. Transplantation proceedings. 2001:33;2327-2329
  6. Tunca A, Erbayrak M, Aytac S, et al.: Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report. Turk J Gastroenterol. 2004;15:97
  7. Ogundipe O, Smith M.: Bell’s palsy during interferon therapy for chronic hepatitis C infection in patients with haemorrahagic disorders. Haemophilia. 2000;6:110-112
  8. Lohmann CP, Kroher G, Bogenrieder T, et al.: Sever loss of vision during adjuvant interferon alfa-2b treatment for malignant melonoma. The Lancet. 1999;353:1326
  9. Burde RM, Savino PJ, Trobe JD.: Optic neuropathies. In Clinical Decisions in Neuro-Ophthalmology. Third edition. 2002. Mosby, St. Louis, Missouri. Chapter 2. 27-58
  10. Kerrison JB.: Optic neuropathies caused by toxins and adverse drag reactions. Ophthalmol Clin North Am. 2004;17:481-488
  11. Guyer DR, Tiedeman J, Yannuzzi LA, et al.: Interferon associated retinopathy. Arch Ophthalmol. 1993;111:350-356
  12. Norcia F, Di Maria A, Prandini F, et al.: Natural interferon therapy: optic nerve ischemic damage?. Ophthalmologica. 1999;213:339-340
  13. Purvin VA.: Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol. 1995;113:1041-1044
  14. Taylor JL, Grossberg SE.: The effects of interferon alpha on the production and action of other cytokines. Semin Oncol. 1998;25:23-29
  15. Cesur M, Gursoy A, Avcioglu U, et al.: Thyrotoxic hypokalemic periodic paralysis as the first manifestation of interferon--induced graves disease. J Clin Gastroenterol. 2006;40:864-865
  16. Jacobson DM, Vierkant RA, Belongia EA.: Nonarteritic anterior ischemic optic neuropathy: a case control study of potential risk factors. Arch Ophthalmol. 1997;115:1043-1047
  17. Nishiwaki H, Ogura Y, Miyamoto K, et al.: Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol. 1996;114:726-730
  18. Salman H, Bergman M